Boehringer Ingelheim GmbH has signed a licensing deal with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments. The agreement could be worth more than $7 billion.
The available information does not specify the treatments covered or provide further details about the terms of the deal.
Sources: Bloomberg Markets.